Table 1.

Demographic and clinical features of the study population

Characteristics	All subjects (n = 41)
Gender
Women, n (%)	22 (54)
Men, n (%)	19 (46)
Age, years	47.4 ± 13.1
Neoadjuvant therapy, n (%)	17 (42)
Adenoma diameter, mm	12 (8 − 21)
Microadenoma, n (%)	12 (29)
Macroadenoma, n (%)	29 (71)
Residual, n (%)	14 (34)
Microadenoma, n (%)	4 (29)
Macroadenoma, n (%)	10 (71)
IGF1, ng/mL; IGF1 (x ULN)
At diagnosis	848 (546 − 1105); 2.9 (1.9 − 3.7)
Three months after NS	249 (194.5 − 424); 0.9 (0.7 − 1.5)
One year after NS	226 (162 − 364); 0.7 (0.6 − 1.2)
Random GH, ng/mL
Postoperative day one	1.4 (0.9 − 2.4)
Postoperative day two	0.9 (0.3 − 1.7)
Three months after NS	1.0 (0.4 − 3.8)
Nadir GH after OGTT, ng/mL
Three months after NS	0.3 (0.1 − 0.8)

Data are presented as the mean ± SD or the median (interquartile range)